TUCSON, Ariz. & ANDOVER, Mass.--(BUSINESS WIRE)--ImaRx Therapeutics, Inc. (Nasdaq: IMRX) and Royal Philips Electronics (NYSE: PHG) (AEX: PHI) today announced a research collaboration to evaluate Philips ultrasound technology as part of ImaRx’s SonoLysis™ program to develop new treatment for acute ischemic stroke. Under the agreement, Philips’ Medical Systems division will provide ultrasound devices and technical assistance to ImaRx during laboratory and preclinical studies. The objective of the collaboration is to determine the optimal ultrasound parameters to use with ImaRx’s proprietary MRX-801 microbubble technology.
